title: The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma.
abstract: Conventional chemotherapy can have a favorable impact on the natural history of disease for selected patients with primary high-risk bone and soft-tissue sarcomas. In particular, multidrug regimens are integral to the care of patients with the most aggressive histologies, including Ewing sarcoma, osteosarcoma, and non-pleomorphic rhabdomyosarcoma. Appropriately selected patients with high-risk, clinically localized soft-tissue sarcomas may also benefit from histology-tailored adjuvant or neoadjuvant therapy. For patients with recurrent disease, conventional chemotherapy is frequently the most appropriate first-line therapy; active drugs are discussed at length. Several new promising cytotoxic chemotherapeutic agents are currently under development, including aldoxorubicin, TH-302, and trabectedin.
authors.affiliation: Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, Columbus, Ohio; Department of Biomedical Informatics, Division of Computational Biology and Bioinformatics, The Ohio State University, Columbus, Ohio.
authors.forename: David A
authors.initials: DA
authors.lastname: Liebner
mesh_terms: D017024:Chemotherapy, Adjuvant; D006801:Humans; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
keywords: adjuvant; conventional chemotherapy; metastatic sarcoma; primary sarcoma; recurrent sarcoma